Co-administration of CG250 and IL-2 or IFN-alpha for treating cancer such as renal cell carcinomas
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 9, 2014
Grant Date -
Jan 14, 2010
app pub date -
Sep 15, 2009
filing date -
Jul 1, 2002
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
A method for enhancing the therapeutic effect of cytokine treatment is disclosed. More specifically the present invention relates to a method for administering to a tumor patient a therapeutic dose of cytokine in combination with antibodies directed against the tumor associated antigen carbonic anhydrase IX (CAIX/G250/MN). The improved treatment method is characterized in a significantly reduced cytokine-related toxicity combined with potentiated effectiveness of anti-G250 antibody alone, resulting in a positive therapeutic response with respect to that observed with single anti-tumor agents alone.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully